Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

E. J.T. Verweij; Abera Tura; Tadesse Gure; Jeremia Pyuza; Bariki Mchome; Kondwani Kawaza; Peter Moons; Derek de Winter; Renske van't Oever; Steven Spitalnik; C. Ellen van der Schoot; Thomas van den Akker

doi:10.1016/s0140-6736(23)01888-3

Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

E. J.T. Verweij, Abera Tura, Tadesse Gure, Jeremia Pyuza, Bariki Mchome, Kondwani Kawaza, Peter Moons, Derek de Winter, Renske van't Oever, Steven Spitalnik, C. Ellen van der Schoot, Thomas van den Akker

Research output: Contribution to journal › Letter › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	806-807
Number of pages	2
Journal	The Lancet
Volume	403
Issue number	10429
DOIs	https://doi.org/10.1016/s0140-6736(23)01888-3
Publication status	Published - 2 Mar 2024
Externally published	Yes

Access to Document

10.1016/s0140-6736(23)01888-3

Cite this

@article{61e117e5587d4623962a56773e1cc92a,

title = "Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy",

author = "Verweij, \{E. J.T.\} and Abera Tura and Tadesse Gure and Jeremia Pyuza and Bariki Mchome and Kondwani Kawaza and Peter Moons and \{de Winter\}, Derek and \{van't Oever\}, Renske and Steven Spitalnik and \{van der Schoot\}, \{C. Ellen\} and \{van den Akker\}, Thomas",

year = "2024",

month = mar,

day = "2",

doi = "10.1016/s0140-6736(23)01888-3",

language = "English",

volume = "403",

pages = "806--807",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10429",

}

TY - JOUR

T1 - Monoclonal RhD prophylaxis: high time to evaluate efficacy: high time to evaluate efficacy

AU - Verweij, E. J.T.

AU - Tura, Abera

AU - Gure, Tadesse

AU - Pyuza, Jeremia

AU - Mchome, Bariki

AU - Kawaza, Kondwani

AU - Moons, Peter

AU - de Winter, Derek

AU - van't Oever, Renske

AU - Spitalnik, Steven

AU - van der Schoot, C. Ellen

AU - van den Akker, Thomas

PY - 2024/3/2

Y1 - 2024/3/2

U2 - 10.1016/s0140-6736(23)01888-3

DO - 10.1016/s0140-6736(23)01888-3

M3 - Letter

SN - 0140-6736

VL - 403

SP - 806

EP - 807

JO - The Lancet

JF - The Lancet

IS - 10429

ER -